Emerging immunotherapies which can re-establish full functionality for CD8+ T cells in the local tumor microenvironment, based primarily on disrupting immunosuppressive PD1/PDL1 interactions, are showing great promise in multiple clinical trials, and have been touted as a game-changer for cancer treatment (9). This evidence concerns the gene CD8A and neoplasm.